{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-226691","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2026-05-15T20:08:23+00:00","discovered_at":"2026-05-15T20:14:00.220925+00:00","generated_at":"2026-05-15T20:14:32.216347+00:00","sec_items":["2.02","3.01","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart","bullets":["Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.","Received Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Nov 9, 2026.","CFO Svai Sanford to resign after successor appointed; separation includes 9 months salary ($491,400) and accelerated vesting.","Phase 1 study of oral GLP-1/GLP-2 dual agonist RT-114 ongoing in obesity; partnered with ProGen.","Appointed new CTO, Head of Strategy, and Strategic Advisor in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-226691","json":"https://secwatch.observer/filing/0001193125-26-226691.json","markdown":"https://secwatch.observer/filing/0001193125-26-226691.md","text":"https://secwatch.observer/filing/0001193125-26-226691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/rani-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:14:32.216347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cae50433de20def5076c2a6826d26e73e90652c","claim":"Rani Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $1.7 million, net income $8.0 million.","evidence_excerpt":"and license agreement with Chugai, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three months ended March 31, 2026 were $1.7 million, compared to $0.2 million for the same period in 2025. The increase of $1.5 million was primarily attributable to the collaboration and license agreement with Chugai. • Research","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$1.7 million"},{"label":"Net income","value":"$8.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7554815e2fa6f1fa17cc67f79069ccfc05146653","claim":"Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (th","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"2a6334860f","claim":"Svai Sanford departed as Chief Financial Officer at Rani Therapeutics Holdings, Inc..","evidence_excerpt":"On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}